汉森制药(002412) - 2021 Q2 - 季度财报

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 443,087,312.44, representing a 42.14% increase compared to CNY 311,730,353.40 in the same period last year[18]. - The net profit attributable to shareholders of the listed company was CNY 70,635,880.51, up 32.70% from CNY 53,230,273.07 in the previous year[18]. - The net cash flow from operating activities reached CNY 115,705,962.98, a significant increase of 206.65% compared to CNY 37,731,814.71 in the same period last year[18]. - The total assets at the end of the reporting period were CNY 2,037,929,328.35, reflecting a 7.90% increase from CNY 1,888,641,664.49 at the end of the previous year[18]. - The net assets attributable to shareholders of the listed company increased by 4.38% to CNY 1,664,522,081.50 from CNY 1,594,720,660.84 at the end of the previous year[18]. - The basic earnings per share for the first half of 2021 were CNY 0.1404, a 32.70% increase from CNY 0.1058 in the same period last year[18]. - Operating profit reached 79.84 million yuan, up 23.38% compared to the same period last year[30]. - The company reported a total of CNY 1,364,669.87 in non-recurring gains and losses during the reporting period[22]. Cash Flow and Financial Management - The company reported a significant increase in cash and cash equivalents, which rose by 354.43% to ¥78,270,772.81, reflecting improved operational cash flow[36]. - The company's cash and cash equivalents increased by 75.58% to ¥181.83 million compared to the beginning of the year[46]. - The cash flow from operating activities generated a net amount of CNY 115,705,962.98, significantly higher than CNY 37,731,814.71 in the previous year[132]. - The company received CNY 100,000,000.00 in borrowings during the first half of 2021, compared to CNY 60,000,000.00 in the same period of 2020[132]. - The company has maintained a cash flow that is relatively abundant, allowing for normal production and operation without significant project expenditures[84]. Market and Product Development - The company is gradually expanding into the health industry and medical care sectors[26]. - The company’s main products include traditional Chinese medicine, chemical drugs, and medical preparations, with a focus on various therapeutic functions[26][27][28][29]. - The company plans to diversify its product offerings, which is expected to support sustained profit growth in the future[36]. - The company is focused on enhancing its health industry park project, reflecting its strategic growth initiatives[94]. - The company plans to continue expanding its market presence and investing in new product development in the upcoming quarters[145]. Risks and Compliance - The company faces risks related to policy changes in the pharmaceutical industry, with significant reliance on its leading product, Si Mo Tang Oral Liquid, which accounts for over 50% of revenue[54]. - The company is actively taking measures to mitigate risks, including optimizing product structure and enhancing market development efforts[57]. - The company plans to strengthen product quality control and adhere to environmental regulations to manage production-related risks[55]. - The company has not engaged in targeted poverty alleviation or rural revitalization efforts during the reporting period, nor are there any subsequent plans[66]. - The company has committed to ensuring the legality and fairness of related party transactions, with strict adherence to relevant laws and regulations[70]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 23,678[100]. - The largest shareholder, Xinjiang Hansen Equity Investment Management Partnership, holds 42.13% of the shares, totaling 212,006,189 shares[100]. - The total number of shares is 503,200,000, with 1.90% being limited sale condition shares and 98.10% being unrestricted sale condition shares[98]. - The number of shares pledged by the largest shareholder is 135,175,000[100]. - The company has not experienced any changes in its controlling shareholder during the reporting period[103]. Accounting and Financial Reporting - The financial report was approved on August 26, 2021, by the 10th meeting of the 5th Board of Directors[151]. - The company adheres to the accounting standards set by the Ministry of Finance, ensuring the financial statements reflect the true financial condition as of June 30, 2021[156]. - The company’s financial statements are prepared based on the accrual basis of accounting, reflecting actual transactions and events[153]. - The company will reassess control definitions if relevant facts and circumstances change, impacting the consolidation scope[166]. - The company applies the equity method for investments in joint ventures, recognizing its share of assets and liabilities[169]. Inventory and Asset Management - Inventory levels increased to CNY 88,583,527.48 from CNY 84,428,766.98, showing a growth of approximately 4.79%[113]. - The company recognizes inventory impairment when the net realizable value is lower than the cost, with provisions made based on the difference for each inventory item[187]. - Non-current assets totaled CNY 1,440,270,094.77, an increase from CNY 1,361,185,499.33, indicating a growth of approximately 5.81%[114]. - The company has not engaged in any asset or equity acquisitions or sales during the reporting period[80]. Research and Development - Research and development expenses increased by 34.06% to ¥17,791,098.85, primarily due to higher costs associated with the consistency evaluation of iodinated contrast agents[35]. - Research and development expenses for the first half of 2021 were CNY 17.79 million, up 33.93% from CNY 13.27 million in the first half of 2020[121]. Other Financial Metrics - The company's financial expenses decreased by 22.14% to ¥2,548,339.80, indicating improved financial management[35]. - The gross profit margin for the pharmaceutical industry was 72.62%, an increase of 1.40% compared to the previous year[40]. - The company reported a total comprehensive income of CNY 68,480,106.67, compared to CNY 49,994,258.63 in the same period last year, reflecting a growth of 37.0%[128].